phrykt

Revolution Medicines, Inc. (RVMD): who owns it and who trades it

As of Nov 16, 2026, RVMD insiders reported 167 open-market sales worth $157M and no purchases in the last 12 months, with 5% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mark A Goldsmith (Director), with $52.6M. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Revolution Medicines

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns RVMD

687 funds and institutions reported RVMD shares worth $40.5B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 6.4%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.6.4%
Farallon Capital Management, L.l.c.6.4%
FMR LLC (Fidelity)5.7%
Baker Bros. Advisors LP5.4%
Jupiter Topco LLC5.1%
Darwin Global Management, Ltd.5.0%
Vanguard Capital Management LLC4.3%
Vanguard Portfolio Management LLC3.9%
Nextech Invest Ltd.3.6%
Paradigm Biocapital Advisors LP3.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.13.70M6.44%$2.6B+22%
Farallon Capital Management, L.l.c.13.55M6.37%$2.5B-0%
FMR LLC (Fidelity)12.20M5.74%$2.3B+44%
Baker Bros. Advisors LP11.44M5.38%$2.1B+20%
Jupiter Topco LLC10.74M5.05%$2B–
Darwin Global Management, Ltd.10.63M5.00%$2B+381%
Vanguard Capital Management LLC9.09M4.28%$1.7B+9%
Vanguard Portfolio Management LLC8.29M3.90%$1.6B+11%
Nextech Invest Ltd.7.60M3.58%$1.4BNo change
Paradigm Biocapital Advisors LP6.36M2.99%$1.2B-4%
UBS Group AG5.45M2.56%$1B+24%
State Street Corp4.90M2.30%$917M+11%
Capital World Investors4.01M1.89%$751M–
Geode Capital Management, LLC3.94M1.85%$737M+18%
Wellington Management Group LLP3.84M1.81%$720M-36%
JPMorgan Chase & Co3.30M1.55%$637M–
Bvf Inc2.97M1.39%$555M+4%
Alphabet Inc.2.95M1.39%$552M-11%
Casdin Capital, LLC2.58M1.21%$483MNo change
Deerfield Management Company, L.P.2.39M1.13%$448M+4%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, RVMD insiders reported $0 of open-market purchases and $157M of sales. 5% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$157M
167 trades, 12 people
Sales under a 10b5-1 plan
5%
Share of sale value
Latest trade
Nov 11, 2026
Filed Nov 13, 2026

Purchases and sales by month

$41.3M$41.3MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 11, 2026Jack AndersCFOSale plan3,499$181.04$633KForm 4
Nov 11, 2026Jack AndersCFOSale plan5,776$182.09$1.1MForm 4
Nov 11, 2026Jack AndersCFOSale plan2,700$182.87$494KForm 4
Nov 11, 2026Jack AndersCFOSale plan1,900$184.02$350KForm 4
Nov 11, 2026Jack AndersCFOSale plan800$185.04$148KForm 4
Nov 11, 2026Jack AndersCFOSale plan400$186.41$74.6KForm 4
Nov 11, 2026Jack AndersCFOSale plan600$187.34$112KForm 4
Nov 11, 2026Jack AndersCFOSale plan200$189.17$37.8KForm 4
Nov 11, 2026Jack AndersCFOSale plan500$190.99$95.5KForm 4
Nov 11, 2026Jack AndersCFOSale plan9,486$191.94$1.8MForm 4
Nov 11, 2026Jack AndersCFOSale plan9,889$192.84$1.9MForm 4
Nov 9, 2026Anthony ManciniSee RemarksSale plan811$200.00$162KForm 4
Oct 26, 2026Anthony ManciniSee RemarksSale plan2,310$186.99$432KForm 4
Sep 29, 2026Alan B. SandlerChief Development OfficeSale plan2,200$200.82$442KForm 4
Sep 29, 2026Alan B. SandlerChief Development OfficeSale plan1,609$201.72$325KForm 4
Sep 29, 2026Alan B. SandlerChief Development OfficeSale plan1,000$202.81$203KForm 4
Sep 29, 2026Alan B. SandlerChief Development OfficeSale plan1,199$203.91$244KForm 4
Sep 29, 2026Alan B. SandlerChief Development OfficeSale plan301$204.72$61.6KForm 4
Sep 25, 2026Jeff CisliniVice presidentSale765$207.32$159KForm 4
Sep 25, 2026Anthony ManciniSee RemarksSale3,121$200.54$626KForm 4
Sep 24, 2026Anthony ManciniSee RemarksSale587$200.00$117KForm 4
Sep 22, 2026Elizabeth M AndersonDirectorSale100$195.15$19.5KForm 4
Sep 22, 2026Elizabeth M AndersonDirectorSale2,648$193.44$512KForm 4
Sep 22, 2026Elizabeth M AndersonDirectorSale4,985$192.54$960KForm 4
Sep 22, 2026Elizabeth M AndersonDirectorSale910$191.85$175KForm 4
Sep 22, 2026Elizabeth M AndersonDirectorSale1,500$194.59$292KForm 4
Sep 18, 2026Anthony ManciniSee RemarksSale1,764$196.94$347KForm 4
Sep 16, 2026Alan B. SandlerChief Development OfficeSale336$199.30$67KForm 4
Sep 16, 2026Alan B. SandlerChief Development OfficeSale5$194.96$975Form 4
Sep 16, 2026Anthony ManciniSee RemarksSale1,747$199.30$348KForm 4
Sep 16, 2026Anthony ManciniSee RemarksSale27$195.05$5.3KForm 4
Sep 16, 2026Stephen Michael KelseySee RemarksSale85$195.01$16.6KForm 4
Sep 16, 2026Stephen Michael KelseySee RemarksSale5,484$199.30$1.1MForm 4
Sep 16, 2026Margaret A HornChief Operating OfficerSale4,891$199.30$975KForm 4
Sep 16, 2026Margaret A HornChief Operating OfficerSale76$195.01$14.8KForm 4
Sep 16, 2026Mark A GoldsmithDirectorSale213$195.01$41.5KForm 4
Sep 16, 2026Mark A GoldsmithDirectorSale13,775$199.30$2.7MForm 4
Sep 16, 2026Jeff CisliniVice presidentSale52$195.01$10.1KForm 4
Sep 16, 2026Jeff CisliniVice presidentSale3,314$199.30$660KForm 4
Sep 16, 2026Jack AndersCFOSale3,992$199.30$796KForm 4
Sep 16, 2026Jack AndersCFOSale61$195.00$11.9KForm 4
Sep 11, 2026Stephen Michael KelseySee RemarksSale3,270$205.81$673KForm 4
Sep 11, 2026Stephen Michael KelseySee RemarksSale4,995$204.84$1MForm 4
Sep 11, 2026Stephen Michael KelseySee RemarksSale17,949$203.87$3.7MForm 4
Sep 11, 2026Stephen Michael KelseySee RemarksSale18,869$203.06$3.8MForm 4
Sep 11, 2026Stephen Michael KelseySee RemarksSale21,447$201.75$4.3MForm 4
Sep 11, 2026Stephen Michael KelseySee RemarksSale13,368$200.78$2.7MForm 4
Sep 11, 2026Stephen Michael KelseySee RemarksSale11,833$200.11$2.4MForm 4
Sep 11, 2026Stephen Michael KelseySee RemarksSale800$198.55$159KForm 4
Sep 10, 2026Anthony ManciniSee RemarksSale2,420$205.05$496KForm 4
Sep 10, 2026Anthony ManciniSee RemarksSale1,179$206.10$243KForm 4
Sep 10, 2026Anthony ManciniSee RemarksSale300$207.17$62.2KForm 4
Sep 10, 2026Anthony ManciniSee RemarksSale6,019$203.28$1.2MForm 4
Sep 10, 2026Anthony ManciniSee RemarksSale5,530$204.14$1.1MForm 4
Sep 8, 2026Lorence H. KimDirectorSale706$206.60$146KForm 4
Sep 8, 2026Lorence H. KimDirectorSale999$207.33$207KForm 4
Sep 8, 2026Lorence H. KimDirectorSale3,587$208.55$748KForm 4
Sep 8, 2026Lorence H. KimDirectorSale371$212.27$78.8KForm 4
Sep 8, 2026Lorence H. KimDirectorSale4,730$210.50$996KForm 4
Sep 8, 2026Lorence H. KimDirectorSale3,844$211.36$812KForm 4
Sep 8, 2026Lorence H. KimDirectorSale2,853$209.56$598KForm 4
Aug 31, 2026Lorence H. KimDirectorSale625$206.15$129KForm 4
Aug 31, 2026Lorence H. KimDirectorSale300$200.56$60.2KForm 4
Aug 31, 2026Lorence H. KimDirectorSale6,597$201.47$1.3MForm 4
Aug 31, 2026Lorence H. KimDirectorSale26,160$203.55$5.3MForm 4
Aug 31, 2026Lorence H. KimDirectorSale7,271$204.35$1.5MForm 4
Aug 31, 2026Lorence H. KimDirectorSale12,919$202.48$2.6MForm 4
Aug 31, 2026Lorence H. KimDirectorSale2,128$205.19$437KForm 4
Aug 21, 2026Jeff CisliniGeneral CounselSale2,540$210.26$534KForm 4
Aug 21, 2026Jeff CisliniGeneral CounselSale3,314$212.06$703KForm 4
Aug 21, 2026Jeff CisliniGeneral CounselSale4,500$211.34$951KForm 4
Aug 21, 2026Jeff CisliniGeneral CounselSale3,400$207.24$705KForm 4
Aug 21, 2026Jeff CisliniGeneral CounselSale25,817$209.25$5.4MForm 4
Aug 21, 2026Jeff CisliniGeneral CounselSale17,323$208.37$3.6MForm 4
Aug 21, 2026Mark A GoldsmithDirectorSale245$211.47$51.8KForm 4
Aug 21, 2026Mark A GoldsmithDirectorSale229$211.46$48.4KForm 4
Aug 21, 2026Mark A GoldsmithDirectorSale126$210.40$26.5KForm 4
Aug 21, 2026Mark A GoldsmithDirectorSale1,405$209.27$294KForm 4
Aug 21, 2026Mark A GoldsmithDirectorSale937$208.36$195KForm 4
Aug 21, 2026Mark A GoldsmithDirectorSale177$207.25$36.7KForm 4
Aug 21, 2026Mark A GoldsmithDirectorSale127$212.06$26.9KForm 4
Aug 21, 2026Mark A GoldsmithDirectorSale126$212.06$26.7KForm 4
Aug 21, 2026Mark A GoldsmithDirectorSale5,128$207.23$1.1MForm 4
Aug 21, 2026Mark A GoldsmithDirectorSale24,917$208.37$5.2MForm 4
Aug 21, 2026Mark A GoldsmithDirectorSale35,938$209.26$7.5MForm 4
Aug 21, 2026Mark A GoldsmithDirectorSale3,813$210.25$802KForm 4
Aug 21, 2026Mark A GoldsmithDirectorSale6,583$211.33$1.4MForm 4
Aug 21, 2026Mark A GoldsmithDirectorSale3,621$212.08$768KForm 4
Aug 21, 2026Mark A GoldsmithDirectorSale190$207.25$39.4KForm 4
Aug 21, 2026Mark A GoldsmithDirectorSale951$208.36$198KForm 4
Aug 21, 2026Mark A GoldsmithDirectorSale1,351$209.28$283KForm 4
Aug 21, 2026Mark A GoldsmithDirectorSale136$210.40$28.6KForm 4
Jun 29, 2026Sushil PatelDirectorSale300$183.17$55KForm 4
Jun 29, 2026Sushil PatelDirectorSale900$184.59$166KForm 4
Jun 29, 2026Sushil PatelDirectorSale1,100$185.90$204KForm 4
Jun 29, 2026Sushil PatelDirectorSale881$192.61$170KForm 4
Jun 29, 2026Sushil PatelDirectorSale300$187.83$56.3KForm 4
Jun 29, 2026Sushil PatelDirectorSale100$188.57$18.9KForm 4
Jun 29, 2026Sushil PatelDirectorSale600$190.55$114KForm 4
Jun 29, 2026Sushil PatelDirectorSale541$191.87$104KForm 4

Latest 100 of 167 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Mark A GoldsmithSee Remarks, Director–$52.6MSep 16, 2026
Margaret A HornChief Operating Officer–$25.3MSep 16, 2026
Stephen Michael KelseySee Remarks–$21.3MSep 16, 2026
Lorence H. KimDirector–$15MSep 8, 2026
Jeff CisliniGeneral Counsel–$14.6MSep 25, 2026
Jack AndersChief Financial Officer–$13.2MNov 11, 2026
Anthony ManciniSee Remarks–$10.4MNov 9, 2026
Elizabeth M AndersonDirector–$2MSep 22, 2026
Alan B. SandlerChief Development Officer–$1.3MSep 29, 2026
Sushil PatelDirector–$1MJun 29, 2026
Lin WeiChief Medical Officer–$206KMar 17, 2026
Xiaolin WangSee Remarks–$200KMar 17, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

RVMD short interest

Moderate short interest. 6.0% of RVMD shares are sold short: about 1 share in 17. Over the last 12 reports the number of shares short went up 18%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 13.08M RVMD shares were sold short, 6.0% of the shares outstanding, up 1.1% from the report before. At the average daily volume of 1.69M shares, buying them all back would take about 7.8 trading days (days to cover).

Shares short, % of all shares

6.05%May 15Oct 306.90%

Days to cover

7.8May 15Oct 308.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202613.08M6.05%+1%1.69M7.8
Oct 15, 202612.93M6.03%+8%2.11M6.1
Sep 30, 202611.93M5.56%+23%2.56M4.7
Sep 15, 20269.67M4.51%-1%1.33M7.2
Aug 31, 20269.73M4.54%+0%2.08M4.7
Aug 14, 20269.72M4.53%-16%1.53M6.4
Jul 31, 202611.52M5.37%-18%1.83M6.3
Jul 15, 202614.00M6.59%+9%2.06M6.8
Jun 30, 202612.88M6.06%+5%4.31M3.0
Jun 15, 202612.28M5.78%+6%2.85M4.3
May 29, 202611.59M5.45%+5%2.75M4.2
May 15, 202611.08M5.21%-13%2.35M4.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Revolution Medicines company events

Revolution Medicines filed 11 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Oct 13, 2026AnnouncementBelow under the heading “Royalty Pharma Tranche A Loan” is incorporated by reference into this Item 2.03. Filing
  3. Sep 1, 2026AgreementRevolution Medicines, Inc. agreed to lease the entirety of four buildings located at 1600, 1700, 1800 and 1900 Seaport Boulevard in Redwood City, California, comprising an aggregate of approximately 672,000 rentable square feet. Filing
  4. Aug 26, 2026AnnouncementThe U.S. Food and Drug Administration approved RASONQUE™ (daraxonrasib) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. Filing
  5. Aug 5, 2026ResultsReleased financial results. Filing
  6. Jun 22, 2026LeadershipSteve Kelsey, M.D., FRCP, FRCPath, informed Revolution Medicines, Inc. of his intent to retire from his employment with the Company effective as of January 4, 2027. Filing
  7. May 6, 2026ResultsReleased financial results. Filing
  8. Apr 17, 2026AgreementRevolution Medicines, Inc. issued $500 million of its 0.50% Convertible Senior Notes due 2033. Filing
  9. Apr 16, 2026AnnouncementRevolution Medicines, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein, to issue and sell 10,563,381 shares of the Company’s common stock, $0.0001 par… Filing
  10. Apr 13, 2026AnnouncementRevolution Medicines, Inc. shared topline results from its global, randomized, controlled Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma who had been previously treated. Filing
  11. Feb 25, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Revolution Medicines financials

Famous investors that hold RVMD

6 of the 50 well-known investors we track reported holding RVMD in their latest 13F filing. The largest position is Ken Griffin's, worth $269M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20261.31M$269M0.1%+122%
Stanley Druckenmiller · Duquesne Family OfficeQ3 2026436,287$89.6M2.2%+9%
Steve Cohen · Point72 Asset ManagementQ3 2026212,971$43.7M0.1%+253%
Ken Fisher · Fisher Asset ManagementQ3 2026134,686$27.6M0.0%-35%
Israel Englander · Millennium ManagementQ3 202681,236$16.7M0.0%-62%
Paul Tudor Jones · Tudor Investment CorpQ3 202616,000$3.3M0.0%No change

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named RVMD in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Baker Bros. Advisors LP13G/A4.9%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A3.5%
Nov 16, 2026Baker Bros. Advisors LP13G/A4.9%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A3.5%
Nov 5, 2026FMR LLC13G/A7.2%
Nov 5, 2026FMR LLC13G/A7.2%
Oct 30, 2026Vanguard Capital Management13G5.1%
Oct 30, 2026Vanguard Capital Management13G5.1%

Questions about Revolution Medicines, Inc. (RVMD) stock

Who owns the most RVMD stock?

The largest reported owner of Revolution Medicines, Inc. (RVMD) is BlackRock, Inc., with 6.4% of the company. In total, 687 funds and institutions reported holding RVMD at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are RVMD insiders buying or selling?

In the last 12 months, RVMD insiders reported no open-market purchases and 167 sales worth $157M. The latest trade was on Nov 11, 2026. See every trade.

What is the short interest in RVMD?

As of Oct 30, 2026, 13.08M RVMD shares were sold short, 6.0% of the shares outstanding, up 1.1% from the report before. At the average daily volume of 1.69M shares, buying them all back would take about 7.8 trading days (days to cover). See the history.

Which famous investors hold RVMD?

6 of the 50 well-known investors we track reported RVMD in their latest 13F filing, including Ken Griffin, Stanley Druckenmiller, Steve Cohen. The largest position is worth $269M. See all holders.

Executive pay

Revolution Medicines's chief executive was paid a total of $14.7M for the year ended Dec 31, 2025, up 46% from $10.1M the year before. In the last 12 months, Revolution Medicines's executives and directors bought no stock on the open market and sold $158M.

Chief executive, total pay$14.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$37.1MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$4.5MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.